Nanobiomedicine: Fundamentals and Implementation in Theranostic Applications

Nanomedicine is a multidisciplinary field merging nanotechnology with medicine to address complicated health challenges at the cellular and molecular levels. The fundamental theory involves operating with materials at the nanoscale (1-100 nanometers), where distinctive physical, chemical, and biological characteristics become apparent. These nanoscale substances can interact with cellular systems in novel ways, allowing precise diagnostics, selective drug delivery, and novel therapeutic methods. Key developments include the progress of nanoparticle-derived delivery systems that enhance the bioavailability and singularity of treatments, decreasing side effects. Nanobiomedicine also plays a crucial role in evaluation and diagnostics, where nanosensors and imaging agents enable the early detection of diseases, including cancer and other infectious diseases. Additionally, nanotechnology has potential in regenerative medicine and tissue engineering, where nanomaterials help in tissue repair and cell growth. Recent advancements, for instance, the incorporation of nanorobots for minimum invasive processes and the utilization of biocompatible nanostructures for customized medications, highlight the revolutionary potential of nanobiomedicine. Although challenges like ethical concerns, toxicity, and regulatory obstacles must be recognised for widespread clinical application, with continuous research, nanobiomedicine promises to transform healthcare, providing more potent, personalized, and reduced invasive medical solutions.

In recent years, nanobiomedicine has emerged as a transformative approach to addressing challenges in diagnosis and therapy. Nanoparticles can act as a vector for drugs and genes in the treatment of various diseases. Their high surface area-to-volume ratio is a positive factor, as it allows the drug- or gene-conjugated nanoparticles to traverse cell membranes and access intracellular targets. Functionalized nanoparticles can target specific cells using receptor-specific recognition, thereby minimizing offtarget effects. Degradation of drugs is common in conventional delivery methods, but nanoparticles help prevent this by encapsulating or shielding the drug formulations. In addition to the aforementioned benefits, nanoparticles can be used to integrate therapy and diagnostics into a single platform, known as theranostics, enabling precise treatment and monitoring of diseases. Both imaging agents and therapeutic molecules (drugs, DNA, and RNA) can be carried by nanoparticles, whose multifunctionality enables simultaneous disease imaging and treatment, reducing the need for separate interventions. Currently, studies are being conducted worldwide on the theranostic potential of nanoparticles under various conditions, ranging from cancer therapy and treatment of genetic disorders to vaccine development, which speaks volumes about their capabilities. In this chapter, we review various nanoparticles used for drug and gene delivery alongside commonly utilized imaging techniques for theranostic applications. 

Using the special phenomenon known as the increased permeability and retention (EPR) effect, the idea of nanomedicine has seen tremendous development in recent decades. Integration of principles based on nanotechnology into diagnostics and medicines has led to major progress in imagining, precision medicine, and targeted delivery of drugs. With a special focus on cancer therapy, countless nanomedicines have been invented and used for the treatment of a variety of diseases. Nanomedicine has recently been applied in a number of cutting-edge sectors, such as tissue engineering, immunotherapy, vaccines, gene transfer, and diagnostics. Concurrent drug administration, therapeutic monitoring, and imaging are made possible by multifunctional nanomedicines, enabling prompt reactions and individualized treatment regimens. This chapter mainly highlights the major progress made in nanomaterials and their probable beneficial uses in the fields of biology and medicine. In addition to this, this chapter also refers to the different clinical translations of nanomedicines and the significant problems that are currently being faced by nanomedicine to overcome the clinical translation barrier.

In the past few years, nanomaterials have emerged tremendously for applications in the field of diagnosis and medicine. They have gained attention due to their extremely small size and mouldable characteristics. This chapter focuses on the different nanomaterials developed for use in diagnostics, treatment, and also as potent drug carriers. These nanomaterials, being very small in size, easily enter circulation to provide the desired therapeutic efficacy or facilitate faster diagnosis. Different nanomaterials, including nanoparticles, nanowires, nanoconjugates, and nanorods, have paved new dimensions in diagnosis and treatment. Not only do they facilitate the detection of diseases by serving as biomarkers, but they also bring to the forefront areas of medicine that were previously difficult to treat or detect using primitive and traditional analytical techniques.

Cancer remains a leading cause of mortality worldwide, necessitating continuous innovation in its diagnosis and treatment. Traditional therapies, including chemotherapy and radiotherapy, face significant limitations such as systemic toxicity, poor selectivity, and drug resistance. Nanomedicine has emerged as a transformative strategy that integrates diagnosis and therapy (theranostics) within a single nanoplatform, enabling targeted drug delivery, stimuli-responsive controlled release of payload, multimodal therapy, and real-time treatment monitoring. This chapter reviews the evolution and applications of various nanomedicine modalities, including polymeric nanoparticles, lipid-based carriers, metallic and silica-based nanoparticles, quantum dots, and Prussian blue nanoparticles, among others. It explores their mechanism of action through both passive and active targeting strategies, discusses the integration of multimodal therapeutic functionalities, and addresses the challenges related to the tumor microenvironment, immune interactions, and clinical translation. Through an analysis of recent advancements and clinical evaluations, this chapter provides a comprehensive understanding of how nanomedicine is redefining cancer care and outlines the prospects and limitations for its widespread implementation in personalized oncology.

The primary reason behind dementia, which is distinguished by a decrease in cognition, freedom within everyday tasks, is Alzheimer's Disease (AD), a disorder that causes brain cells to deteriorate. AD is addressed as a complex illness, with the cholinergic and amyloid hypotheses proposed as two primary theories underlying its pathology.. Additionally, a number of risk factors, such as aging, genetics, head trauma, vascular disease, pollution, as well as environmental elements, all participate in the illness. In this chapter, we have presented machine learning-based automatic identification of Alzheimer’s Disease (AD). As features, Socioeconomic Status, MiniMental State Examination, Estimated total intracranial volume, Normalized wholebrain volume, and the Clinical Dementia Rating have been used. For classification, the KNN classifier has been used with different distance metrics and by varying the number of K-values. Here are mainly three types of distance metrics: Euclidean distance, Manhattan distance, and Minkowski distance, among others, to compute the performance measures of Accuracy, Recall, Precision, and F1-values.

Nanomaterials have been extensively investigated to be used in clinical and pharmaceutical applications due to their unique features, such as shape, size, surface properties, reactive oxygen species (ROS) scavenging, targeted drug delivery, improved cell imaging due to excellent fluorescence property, precise personalized diagnosis, reduced side effects, and excellent sensing property. Despite all advantages, nanomaterials are signified as a potential generator of ROS, a symbol of toxicity. Although some clinical practices utilize ROS to prevent cancer, bacterial infection, etc., non-customized morphology can yield excessive ROS that may cause harm to normal cells. Another disadvantage is the infant research stages; more modulation in design is needed, and evaluation, as well as validation in nanotoxicity, is required. Although there exist a few stories of nano-medicine-mediated theranostic applications, the emerging challenges are increasingly prompting researchers to explore the optimal use of artificial intelligence (AI) in designing personalized drug delivery systems, potentially offering a more effective alternative to traditional nano-theranostic approaches. Accordingly, an elaborate governance framework is needed to develop and implement innovative AI systems successfully in the healthcare sector. The present work provides a comprehensive overview of the role of AI technologies in drug delivery, along with its ethical and regulatory concerns. Additionally, it illuminates the numerous challenges met in the employment of AI systems in clinical practice.

Artificial intelligence is emerging as a transformative factor in the development of nanomedicine—the integration of nanotechnology and biomedical science to solve complex health problems. This paper reports on the synergistic integration of AI and nanomedicine, with a focus on the contributions it makes towards creating nanoscale materials, upgrading nanomaterials, and applications in diagnostics, drug delivery, and regenerative therapy. AI-driven approaches rapidly identify the ideal properties of nanomaterials, enhance the interaction between drugs and nanoparticles, and improve the accuracy of their mechanism for targeting diseases. Here, predictive modeling using machine learning algorithms accelerates progress in nanocarriers, nanosensors, and imaging technologies, while providing an opportunity to detect diseases at early stages and customize targeted therapeutic strategies [1].

The article highlights revolutionary breakthroughs enabled by AI in addressing the aforementioned limitations of nanomedicine, specifically in terms of production scales, regulatory burdens, and nano-material toxicity. Case studies illustrating AI-driven breakthroughs in treatments for cancer, cardiovascular diseases, and neurological disorders describe improved clinical results through targeted and advanced diagnostics and treatments. However, the convergence of AI and nanomedicine also raises ethical, regulatory, and data-related issues that require interdisciplinary collaboration and robust frameworks for responsible implementation. This study highlights the potential of AI in transforming nanomedicine, paving the way for next-generation medical solutions that are more secure, efficient, and tailored to meet the unique needs of patients. By connecting computational technologies with biomedical applications, the research envisions a future in which AI-driven nanomedicine revolutionizes healthcare delivery worldwide [2].